We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Onzima Ventures | LSE:ONZ | London | Ordinary Share | GB00BYQCDH57 | ORD 0.1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 1.25 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
TIDMONZ
RNS Number : 9241D
Onzima Ventures PLC
02 May 2017
02 May 2017
Onzima Ventures plc (to be re-named N4 Pharma Plc)
(the "Company")
Result of General Meeting, Directorate Changes, Share Re-organisation, Change of Name and Website address and Voting Rights
Result of General Meeting
The Company is pleased to announce that all resolutions put to Shareholders at the General Meeting held earlier today were duly passed and therefore completion of the acquisition of N4 Pharma Limited is expected to take place on 3 May 2017.
Directorate Changes
Following the passing of the resolutions as set out above, the Company announces, each with effect upon Admission, the resignations of Gavin Burnell, Chief Executive, and Professor Humayun Mughal, Non-Executive Director, as directors of the Company and the appointments of David Templeton, Non-Executive Chairman, Nigel Theobald, Chief Executive, and Paul Titley, Executive Director, as directors of the Company. Further details on the newly appointed directors are set out in the Appendix below.
Share Re-organisation
At the General Meeting, Shareholders approved the Share Re-organisation which is expected to take place after close of business on the Record Date, being 2 May 2017. Fractional entitlements resulting from the Share Re-organisation will be sold for the benefit of Shareholders other than amounts of less than GBP5.00 which the Company will retain for its own benefit.
Change of Name and Website Address
At the General Meeting, Shareholders also approved the change of the Company's name from Onzima Ventures Plc to N4 Pharma Plc. The change of name will be effective once Companies House has issued a certificate of incorporation on change of name which is expected to occur by Admission. The Company's AIM symbol will change to N4P with effect from 8.00am on 3 May 2017.
Following the change of the Company's name becoming effective, its website address, which will include the information required by AIM Rule 26, will be www.n4pharma.com.
Voting Rights
Application has been made for the Enlarged Share Capital to be admitted to trading on AIM. It is expected that restoration of trading on AIM in the Existing Ordinary Shares and Admission will become effective and that dealings in the Enlarged Share Capital will commence at 8.00am on 3 May 2017.
Following completion of the Company's Share Re-organisation and Admission, the Enlarged Share Capital will comprise 71,714,285 Ordinary Shares. Each Ordinary Share has one voting right. No Ordinary Shares are held in treasury. Accordingly, the total number of voting rights will be 71,714,285.
The above figure may be used by Shareholders as the denominator for the calculation by which they will determine if they are required to notify their interest in, or a change to their interest in, N4 Pharma plc under the FCA's Disclosure Guidance and Transparency Rules.
Defined terms used in this announcement shall have the same meaning as in the Company's admission document published on 13 April 2017, copies of which are available on the Company's website.
Enquiries:
N4 Pharma Nigel Theobald, Via Alma PR CEO Stockdale Securities Tom Griffiths Tel: +44(0)207 601 6100 Beaufort Securities Elliot Hance Tel: +44(0)207 382 8300 Alma PR Josh Royston Tel: +44(0)778 090 Robyn Fisher 1979 Tel: +44(0)754 070 6191
Appendix
The following information is disclosed pursuant to Schedule Two paragraph (g) of the AIM Rules for Companies. The newly appointed Directors, as mentioned above, hold or have held the following directorships or have been partners in the following partnerships within the past five years:
Name Current Directorships/Partnerships Past Directorships/Partnerships ---------------- ----------------------------------- -------------------------------- David Templeton None DT Pharmacology Consultancy Limited ---------------- ----------------------------------- -------------------------------- Nigel Theobald Askalane Limited Oxford Nutra Limited Lytegro Limited Oxford Pharmascience Medherant Limited Group Plc N4 Pharma Limited Oxford Pharmascience Limited ---------------- ----------------------------------- -------------------------------- Paul Titley Critical Pharmaceuticals Aesica Formulation Development Limited Keswick Community Asset Company Keswick Museum and Art Gallery N4 Pharma Limited ---------------- ----------------------------------- --------------------------------
In addition, as at the date of this announcement, Nigel Theobald holds 29,893,963 Existing Ordinary Shares, representing approximately 16.1 per cent of the Existing Ordinary Share Capital.
There is no other information that is required to be disclosed pursuant to Schedule 2 paragraph (g) of the AIM Rules for Companies.
This information is provided by RNS
The company news service from the London Stock Exchange
END
ROMLLFIVEFIFIID
(END) Dow Jones Newswires
May 02, 2017 09:06 ET (13:06 GMT)
1 Year Onzima Ventures Chart |
1 Month Onzima Ventures Chart |
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions